TGR-1202 for Chronic Lymphocytic Leukemia (UNITY-CLL Trial)

"There are one hundred and twenty-three studies underway for Ublituximab; with 23 of those in the third stage of clinical trials. Although a majority of these trials take place in Boston, Massachusetts, there are 5292 locations running trials for this treatment globally."

"No, this specific trial is not currently looking for candidates according to the latest update on clinicaltrials.gov from October 19th, 2022. This does not mean there are no other trials recruiting, in fact, there are 1698 medical studies presently accepting participants."

"Lymphoma patients may respond well to ublituximab, which is also being trialed for its efficacy against indolent lymphoma, malt lymphoma, and hodgkin disease."

"Ublituximab's journey from research to drug approval spanned 7 years and began in 2012. That year, Janssen Research & Development, LLC sponsored the first study into Ublituximab which involved 232 participants. The next milestone for Ublituximab was Phase 3 drug approval which it received after its first study. As of today, there are 123 live studies being conducted with Ublituximab across 51 countries and 1019 cities"

"Unfortunately, this particular trial has stopped recruiting patients. The study was first made available on November 19th, 2015 but the last update was on October 19th, 2022. There are other trials underway though – 1575 for leukemia and 123 specifically for Ublituximab."

"Ublituximab has undergone Phase 3 trials, meaning that there is evidence of its efficacy and multiple rounds of data supporting its safety. Consequently, our team rates it a 3 in terms of safety."

"100 clinical trial sites are currently enrolling patients for this study. While some cities, such as Detroit, Camp Hill and Wauwatosa have multiple locations, other participating towns only have a single site. It may be beneficial to select the location nearest you in order to limit travel if you choose to participate."